Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing- remitting multiple sclerosis

Annals of Neurology

Volumn 43, Issue 1, 1998, Pages 116-120

  Zipp, Frauke ^a   Weller, Michael ^a   Calabresi, Peter A ^b   Frank, Joseph A ^b   Bash, Craig N ^b   Dichgans, Johannes ^a   McFarland, Henry F ^b   Martin, Roland ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; FAS ANTIGEN;

ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISABILITY; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NERVE LESION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT DISEASE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; ANTIBODY FORMATION; ANTIGENS, CD95; COHORT STUDIES; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; RECURRENCE; REFERENCE VALUES; TREATMENT OUTCOME;

EID: 0031915404     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430120     Document Type: Article

References (19)

1. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10: 153-187.
2. Zipp F, Weber F, Huber S, et al. Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-α by HLA-DR2+ T cells. Ann Neurol 1995;38: 723-730.
3. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T Cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990;247:718-721.
4. Zhang J, Markovic-Plese S, Lacet B, et al. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994;179:973-984.
5. Drappa J, Vaishnaw AK, Sullivan KE, et al. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996;335:1643-1649.
6. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263:1759-1762.
7. Goel N, Ulrich DT, St. Clair EW, et al. Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 1995;38:1738-1743.
8. Knipping E, Krammer PH, Onel KB, et al. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 1995;38:1735-1737.
9. Poser CM, Pary DW, Scheinberg L. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol 1983;13: 1444-1452.
11. Stone LA, Frank JA, Albert PA, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-619.
12. Inoue A, Koh C, Sakai T, et al. Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. J Neuroimmunol 1997;75:141-146.
13. Weller M, Malipiero U, Rensing-Ehl A, et al. Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 1995;55: 2936-2944.
14. D'Souza SD, Bonetti B, Balasingam V, et al. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J Exp Med 1996; 184:2361-2370.
15. Dowling P, Shang G, Raval S, et al. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 1996;184:1513-1518.
16. Pender MP, Nguyen KB, McCombe PA, Kerr JFR. Apoptosis in the nervous system in experimental allergic encephalomyelitis. J Neurol Sci 1991;104:81-87.
17. Selleri C, Sato T, Del Vecchio L, et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia. Blood 1997;89:957-964.
18. Sheridan JP, Marsters S, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-821.
19. Pan G, Ni J, Wei Y, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277:815-818.